Passage Bio, Inc.

PASGNASDAQHealthcare● Active

$5.47

$-0.15(-2.67%)

Market Cap$17546721

P/E Ratio—

52W High$20

52W Low$3.935

Avg Volume79K

Open$5.69

Beta1.41

Insider Trades Ownership Employees

Passage Bio, Inc. (PASG) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · PASG · as of Jun 9, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.55

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 35%Active transactions only · RSU vesting excluded65% Sell ↓

Passage Bio, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

PASG insider buying and selling by quarter

PASG insider selling · PASG insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

1.4M687K0

2024 Q2

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Active insiders

Most active in past 12 months · PASG ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

PASG executive sell shares · PASG board member insider trading · PASG insider trading SEC filing

Showing 49 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Jan 8, 2026	Chou William PRESIDENT AND CEO · Director	Option	10,000	—	—	10,600	Form 4
Jan 8, 2026	Chou William PRESIDENT AND CEO · Director	Sale	4,076	$18.44	$75K	6,524	Form 4
Jan 8, 2026	Borthwick Kathleen CFO	Option	5,000	—	—	7,464	Form 4
Jan 8, 2026	Borthwick Kathleen CFO	Sale	2,062	$18.44	$38K	5,402	Form 4
Sep 15, 2025	Lynx1 Capital Management LP 10 percent owner	Purchase	11,900	$6.99	$83K	623,704	Form 4
Sep 12, 2025	Lynx1 Capital Management LP 10 percent owner	Purchase	19,783	$6.99	$138K	611,804	Form 4
Jul 24, 2025	Lynx1 Capital Management LP 10 percent owner	Purchase	66,423	$5.71	$379K	591,696	Form 4
Jul 23, 2025	Lynx1 Capital Management LP 10 percent owner	Purchase	49,302	$5.74	$283K	525,273	Form 4
Jun 24, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	231,600	$0.35	$81K	6,418,400	Form 4
Jun 25, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	138,800	$0.33	$46K	6,279,600	Form 4
Jun 26, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	213,257	$0.33	$70K	6,066,343	Form 4
Apr 22, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	78,049	$0.34	$27K	6,807,523	Form 4
Apr 23, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	89,328	$0.34	$30K	6,718,195	Form 4
Apr 24, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	68,195	$0.32	$22K	6,650,000	Form 4
Apr 15, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	10,326	$0.38	$4K	7,024,300	Form 4
Apr 16, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	61,638	$0.33	$20K	6,962,662	Form 4
Apr 17, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	77,090	$0.33	$25K	6,885,572	Form 4
Feb 10, 2025	Borthwick Kathleen CFO	Option	8,000	—	—	44,466	Form 4
Feb 11, 2025	Borthwick Kathleen CFO	Sale	3,183	$0.53	$2K	41,283	Form 4
Jan 10, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	126,209	$0.66	$83K	7,131,636	Form 4
Jan 13, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	17,986	$0.64	$12K	7,113,650	Form 4
Jan 14, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	79,024	$0.60	$47K	7,034,626	Form 4
Jan 6, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	19,481	$0.77	$15K	7,385,388	Form 4
Jan 7, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	52,536	$0.71	$37K	7,332,852	Form 4
Jan 8, 2025	ORBIMED ADVISORS LLC 10 percent owner	Sale	75,007	$0.68	$51K	7,257,845	Form 4

Chou William

PRESIDENT AND CEO · Director

Option

Date

Jan 8

10,000

Price

—

Value

—

View Form 4 on SEC.gov

Chou William

PRESIDENT AND CEO · Director

Sale

Date

Jan 8

4,076

Price

$18.44

Value

$75K

View Form 4 on SEC.gov

Borthwick Kathleen

CFO

Option

Date

Jan 8

5,000

Price

—

Value

—

View Form 4 on SEC.gov

Borthwick Kathleen

CFO

Sale

Date

Jan 8

2,062

Price

$18.44

Value

$38K

View Form 4 on SEC.gov

Lynx1 Capital Management LP

10 percent owner

Purchase

Date

Sep 15

11,900

Price

$6.99

Value

$83K

View Form 4 on SEC.gov

Lynx1 Capital Management LP

10 percent owner

Purchase

Date

Sep 12

19,783

Price

$6.99

Value

$138K

View Form 4 on SEC.gov

Lynx1 Capital Management LP

10 percent owner

Purchase

Date

Jul 24

66,423

Price

$5.71

Value

$379K

View Form 4 on SEC.gov

Lynx1 Capital Management LP

10 percent owner

Purchase

Date

Jul 23

49,302

Price

$5.74

Value

$283K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Jun 24

231,600

Price

$0.35

Value

$81K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Jun 25

138,800

Price

$0.33

Value

$46K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Jun 26

213,257

Price

$0.33

Value

$70K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Apr 22

78,049

Price

$0.34

Value

$27K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Apr 23

89,328

Price

$0.34

Value

$30K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Apr 24

68,195

Price

$0.32

Value

$22K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Apr 15

10,326

Price

$0.38

Value

$4K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Apr 16

61,638

Price

$0.33

Value

$20K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Apr 17

77,090

Price

$0.33

Value

$25K

View Form 4 on SEC.gov

Borthwick Kathleen

CFO

Option

Date

Feb 10

8,000

Price

—

Value

—

View Form 4 on SEC.gov

Borthwick Kathleen

CFO

Sale

Date

Feb 11

3,183

Price

$0.53

Value

$2K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Jan 10

126,209

Price

$0.66

Value

$83K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Jan 13

17,986

Price

$0.64

Value

$12K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Jan 14

79,024

Price

$0.60

Value

$47K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Jan 6

19,481

Price

$0.77

Value

$15K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Jan 7

52,536

Price

$0.71

Value

$37K

View Form 4 on SEC.gov

ORBIMED ADVISORS LLC

10 percent owner

Sale

Date

Jan 8

75,007

Price

$0.68

Value

$51K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 2

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About PASG insider trading

PASG insider trades

Passage Bio, Inc. (PASG) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Lynx1 Capital Management LP (10 percent owner), ORBIMED ADVISORS LLC (10 percent owner), Chou William (PRESIDENT AND CEO · Director). Over the past 12 months, 4 insiders have filed transactions with the SEC. PASG insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Passage Bio, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

PASG insider trading · 5 questions

The insiders of Passage Bio, Inc. (PASG) include executives and directors such as Lynx1 Capital Management LP (10 percent owner), ORBIMED ADVISORS LLC (10 percent owner), Chou William (PRESIDENT AND CEO · Director), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

PASG board member insider tradingwho are PASG insidersPASG insider rosterPassage Bio, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026